Have a symptom?
See what questions
a doctor would ask.

Prevalence and Incidence of X-Linked Agammaglobulinemia

Prevalance of X-Linked Agammaglobulinemia:

1-in-100,000 ... see also overview of X-Linked Agammaglobulinemia.

Prevalance Rate:

approx 1 in 100,000 or 0.00% or 2,720 people in USA [Source statistic for calcuation: "1-in-100,000" -- see also general information about data sources]

X-Linked Agammaglobulinemia: Rare Disease

X-Linked Agammaglobulinemia is listed as a "rare disease" by the Office of Rare Diseases (ORD) of the National Institutes of Health (NIH). This means that X-Linked Agammaglobulinemia, or a subtype of X-Linked Agammaglobulinemia, affects less than 200,000 people in the US population.

Prevalance of X-Linked Agammaglobulinemia:

One out of 100,000 people have XLA. (Source: excerpt from Primary Immune Deficiency, NIAID Fact Sheet: NIAID)

About prevalence and incidence statistics:

The term 'prevalence' of X-Linked Agammaglobulinemia usually refers to the estimated population of people who are managing X-Linked Agammaglobulinemia at any given time. The term 'incidence' of X-Linked Agammaglobulinemia refers to the annual diagnosis rate, or the number of new cases of X-Linked Agammaglobulinemia diagnosed each year. Hence, these two statistics types can differ: a short-lived disease like flu can have high annual incidence but low prevalence, but a life-long disease like diabetes has a low annual incidence but high prevalence. For more information see about prevalence and incidence statistics.


By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise